CliffBio
small molecule

MOTEGRITY

PRUCALOPRIDE SUCCINATE

Loss of exclusivityJuly 2028FDA regulatory exclusivity expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameMOTEGRITY
Active ingredientPRUCALOPRIDE SUCCINATE
StrengthEQ 2MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2018
Marketing statusRX

Regulatory exclusivity

CodeExpires
M-14July 2028

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.